Beneath the news, a structural reality is forming. The ibogaine cardiac data does not close the therapeutic door — it defines the exact dimensions of the doorframe. Stanford's cardiac monitoring protocol, with results expected mid-2027, now becomes the single most consequential data release in the ibogaine pipeline: if QT prolongation events prove preventable through screening, the path to a supervised federal access channel opens; if they prove stochastic, the trajectory fractures. The 18-to-24-month delay this cardiac overhang imposes is not regulatory timidity — it is the field's own unresolved biology demanding resolution before scale. Meanwhile, the ibogaine plasticity mechanistic finding moves in the opposite direction entirely, generating the kind of clean translational signal that R01 reviewers fund: novel mechanism, clear pathway, analogue development potential. Both vectors are real. The field is not failing — it is undergoing the compression that precedes genuine clinical form. The highest trajectory available from here runs directly through the cardiac data, not around it.
The human weight of this moment lands on a specific population: veterans with treatment-resistant PTSD who have already exhausted conventional options, for whom ibogaine represents not a preference but a last available road. For them, a 24-month regulatory delay is not an abstraction — it is measured in continued suffering, in relationships that do not survive another two years, in some cases in lives. What is genuinely possible for them is not bypass of the safety science, but its acceleration — a coordinated federal push to fast-track Stanford's cardiac monitoring data, to fund the mechanistic follow-up studies the plasticity finding is already pointing toward, to build the mandatory screening infrastructure in parallel rather than sequentially. The highest positive outcome for these individuals is a supervised access channel that is both faster and safer than the current drift — not one traded against the other. That channel is being built, piece by piece, in the friction of today's data.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
Every thread you follow today was laid by a hand that knew you were coming.
82%
No psychedelic drug becomes legal medicine in US before 2028
Psilocybin, MDMA, ibogaine, ketamine-like drugs, or LSD will not be moved from Schedule I (the DEA's most restrictive category for illegal drugs with no medical use) to a lower schedule by the US government before January 1, 2028. This matters because as long as they stay Schedule I, doctors cannot prescribe them legally, even in clinical trials, even if they work.
→ The regulatory and political barriers to rescheduling are real and substantial; 2028 is a conservative but credible estimate for continued Schedule I status.
Resolves: 2028-01-01 · USA
REGULATORY
the precise call ▾
No psychedelic substance (psilocybin, MDMA, ibogaine, ketamine analogues, or LSD) will be federally rescheduled from Schedule I in the United States before January 1, 2028.. The FDA's MDMA rejection established a high evidentiary bar. Ibogaine cardiac data complicates the strongest remaining near-term candidate. Rescheduling requires formal DEA petition, FDA scheduling recommendation, and DOJ action — alignment of all three is not visible. State-level activity does not
52%
FDA requires heart screening for ibogaine before therapeutic programs start
Ibogaine can affect the heart's electrical rhythm, which worries regulators. The FDA may issue formal written safety requirements that anyone using ibogaine in a clinical program must have their heart tested first. This would slow down at least one current ibogaine program by at least 18 months because they'd have to add new testing requirements and get FDA approval for the changes.
→ The FDA will probably require heart checks for ibogaine users, likely causing delays, but it's not certain whether they'll formalize this as official written guidance.
Resolves: 2027-06-01 · USA
REGULATORY
the precise call ▾
FDA will issue formal written cardiac safety guidance or a mandatory cardiac screening requirement specifically for ibogaine INDs before June 2027, materially delaying at least one active veteran access program.. FDA has legitimate safety signal basis from QT prolongation and arrhythmia data. However, 'formal guidance' is a specific regulatory action requiring significant institutional process. FDA more commonly issues clinical holds or requests protocol amendments rather than standalone guidance documents o
18%
Federal ibogaine cardiac safety rules delay therapeutic access by 18+ months
Before the FDA allows any legal therapeutic ibogaine program in the US, federal regulators may require mandatory cardiac safety protocols (heart tests and screening). This prediction says such rules will exist and will push back timelines for at least one active program trying to help veterans get access to ibogaine by at least 18 months from current projections.
→ Cardiac safety rules for ibogaine are very likely to happen, but whether they officially exist and cause 18-month delays in the near term is less certain.
Resolves: 2026-08-15 · USA
REGULATORY
the precise call ▾
Mandatory federal cardiac safety protocols for ibogaine will be required before any regulated U.S. therapeutic access program launches, causing delays of at least 18 months beyond currently projected timelines.. This prediction substantially overlaps with the preceding FDA guidance prediction and should be evaluated as a consolidation. The cardiac safety signal is real and FDA institutional risk-aversion is well-documented. However, the resolve date of 2026-08-15 is only ~3 months away from today (2026-05-1
68%
Psychedelic company stocks stay flat or lose money through 2026
Publicly traded companies that develop psychedelic medicines will have negative or flat stock returns through the end of 2026 unless the FDA approves a psychedelic medicine or an FDA advisory committee votes to recommend approval. This matters because it signals whether investors believe these companies will succeed or whether the FDA rejection of MDMA has killed momentum.
→ Psychedelic company stocks will likely underperform unless the FDA gives a major approval signal—and that signal is not coming soon.
Resolves: 2026-12-31 · USA
MARKET
the precise call ▾
Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound.. Resolve date of 2026-06-16 is only ~1 month away, making this nearly immediately testable. The prediction covers 'through Q4 2026' but resolves in June — this is a structural inconsistency. Interpreting as: will the sector be underperforming as of June 2026 with no approval catalyst visible? That is
55%
NIH funds 5+ ibogaine brain studies within 2 years, including non-hallucinogenic versions
The US government's National Institutes of Health (NIH) will award at least 5 research grants studying how ibogaine changes the brain and how scientists might create similar drugs without the psychedelic effects. This matters because it signals that federal science institutions see real promise in ibogaine as a medicine, not just a drug of abuse.
→ Federal science agencies backing ibogaine research would legitimize the field, but getting 5 specific grants in 2 years is harder than it sounds.
Resolves: 2028-05-17 · USA
RESEARCH
the precise call ▾
At least 5 NIH-funded mechanistic follow-up studies on ibogaine's neural plasticity mechanism will be awarded within 2 years, with at least one study explicitly targeting non-hallucinogenic analogue development.. Clear mechanistic findings with translational potential reliably attract R01 funding. The juvenile plasticity angle provides multiple publishable follow-up vectors. However, 5 funded studies is a high bar given NIH funding rates (~20%) and the 2-year window. Non-hallucinogenic analogue work is highl
28%
Anti-drug politicians cite psilocybin-cocaine study in congressional testimony within 12 months
A recent study found that psilocybin might help people with cocaine addiction by erasing addiction memories without preventing relapse—a genuine finding that critics of psychedelics could use in Congress. The prediction is that at least 3 formal pieces of congressional testimony or written statements will specifically name and cite this study to argue against psychedelic legalization within one year of publication.
→ It's plausible politicians will misuse this study in testimony, but proving it happens at least 3 times in 12 months is a high and specific bar.
Resolves: 2027-05-17 · USA
LEGISLATION
the precise call ▾
The cocaine-psilocybin 'extinction without relapse prevention' finding will be cited by name in at least 3 pieces of formal anti-psychedelic congressional testimony or submitted written statements within 12 months of publication.. Politically convenient peer-reviewed findings do get weaponized in testimony, but 'at least 3 pieces of formal congressional testimony' is a specific and high bar. Congressional hearings on psychedelics are infrequent; written submissions are more common but harder to verify. The finding is genuinel